BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 11, 2009
View Archived Issues
Exelixis, BI Enter Autoimmune Agreement Worth up to $354M
Exelixis Inc. and German drugmaker Boehringer Ingelheim GmbH entered a deal potentially worth $354 million to discover, develop and commercialize autoimmune disease therapies. (BioWorld Today)
Read More
Biotech Clusters Face Challenges, but Jobs and Capital Still Exist
Read More
H1N1 Swine, H5N1 Bird Flu Both Still Long Way from Pandemic
Read More
Dendreon Offering Raises $230M for Provenge Launch Preparation
Read More
CDC: H1N1 Bullet Not Dodged Just Yet, Threat not Over
Read More
Other News To Note
Read More
Clinic Roundup
Read More